The use of “omics” to guide the selection of targeted therapy

Abstract

In this book, the role of many different proteins, pathways, or genetic events in affecting the function of leukemic cells, as well as their suitability for therapeutic modulation, is discussed. However, since acute myeloid leukemia (AML) is a very heterogeneous disease, it will be necessary to match the characteristics of individual patients to the selection of the right targeted agent in order to maximizen efficacy. In this chapter, we discuss how the application of the numerous molecular profiling arrays that are now available can be utilized to provide the answer to this dilemma. The development of methods to combine data from multiple arrays, termed “integromics” will enable a more sophisticated application of “omic” data that will facilitate the selection of combinations of targeted agents on an individualized basis.